Vivani Medical, Inc. (VANI)
(Delayed Data from NSDQ)
$1.25 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.25 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VANI 1.25 0.00(0.00%)
Will VANI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VANI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for VANI
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
Analysts Are Bullish on Top Healthcare Stocks: Vivani Medical (VANI), Shattuck Labs (STTK)
Vivani Medical gains as FDA lifts clinical hold on GLP-1 implant
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's IND Gains FDA Clearance For Clinical Use (UPDATED)